Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.45 |
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313989 | 0.95 | CNR2 (0.47) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL5780701 | 0.90 | ITGB3 (0.44) | CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL5780511 | 0.89 | CNR2 (0.42) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL5776987 | 0.88 | ITGB3 (0.47) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL5780692 | 0.86 | ITGAV (0.55) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL5778299 | 0.86 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL5778812 | 0.86 | ITGB3 (0.45) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL1071434 | 0.85 | ITGB3 (0.39) | CNR2ITGB3ITGAVITGA2B | |
| SCHEMBL5780950 | 0.82 | ITGB3 (0.42) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL5779990 | 0.79 | ITGB3 (0.41) | CNR1ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944619-B1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-10-11 | — | — | EP | claimed |
| EP-0944619-B1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6358976-B1 | FOR THERAPY AND PROPHYLAXIS OF CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, OR MACULAR DEGENERATION | LANTHEUS MI REAL ESTATE, LLC | 2002-03-19 | — | — | US | disclosed |
| US-6130231-A | SUBSTITUTED 2,3-DIHYDROQUINOLIN-4-ONES | DUPONT PHARMACEUTICALS (US) | 2000-10-10 | — | — | US | disclosed |